Cambridge, United Kingdom – May 22, 2026
AstraZeneca and Daiichi Sankyo announced that the U.S. Food and Drug Administration (FDA) has approved Datroway® (datopotamab deruxtecan) as the first TROP2-directed antibody-drug conjugate (ADC) for the first-line treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. The approval marks a major advancement in precision oncology and introduces a new treatment option for one of the most aggressive and difficult-to-treat forms of breast cancer.
The approval was granted following FDA Priority Review based on results from the global Phase III TROPION-Breast02 trial, where Datroway demonstrated significant improvements in overall survival and progression-free survival compared with standard chemotherapy. Oncology experts believe the approval could redefine the treatment landscape for metastatic TNBC patients who historically had limited therapeutic options beyond chemotherapy.
Datroway Demonstrates Strong Survival Benefits in Phase III Trial
In the TROPION-Breast02 trial, Datroway achieved a statistically significant and clinically meaningful 5.0-month improvement in median overall survival compared with chemotherapy in previously untreated metastatic TNBC patients who were not eligible for immunotherapy. The therapy also reduced the risk of disease progression or death by 43% and delivered a substantially higher objective response rate of 64%, compared with 30% in the chemotherapy group.
Researchers noted that Datroway became the first and only medicine to significantly prolong overall survival in this specific first-line metastatic TNBC setting. The therapy achieved an unprecedented median overall survival of approximately two years, positioning it as a potential new standard of care for patients who previously faced poor long-term outcomes.
Advertisement
The safety profile observed in the trial remained consistent with previous Datroway studies in breast cancer, supporting continued development across additional solid tumor indications. Regulatory reviews are also ongoing in the European Union, China, Japan, Australia, Canada, Singapore, and Switzerland under international oncology review frameworks including Project Orbis.
TROP2-Directed ADC Technology Expands Precision Oncology
Datroway is a specifically engineered TROP2-directed DXd antibody-drug conjugate, developed using Daiichi Sankyo’s proprietary ADC technology platform and jointly commercialized with AstraZeneca. The treatment combines a humanized monoclonal antibody targeting the TROP2 protein with a potent topoisomerase I inhibitor payload, enabling selective delivery of chemotherapy directly into cancer cells while limiting damage to healthy tissue.
Triple-negative breast cancer accounts for approximately 15% of all breast cancer cases globally and is considered one of the most aggressive breast cancer subtypes. Because TNBC lacks estrogen receptors, progesterone receptors, and HER2 overexpression, treatment options are significantly more limited than in other breast cancer forms. Prior to Datroway’s approval, chemotherapy remained the primary first-line treatment option for nearly 70% of metastatic TNBC patients who were not eligible for immunotherapy.
Industry analysts view antibody-drug conjugates as one of the fastest-growing segments in oncology due to their ability to combine the targeting precision of biologics with the cancer-killing potency of chemotherapy. AstraZeneca and Daiichi Sankyo continue expanding Datroway’s development program through more than 20 global clinical trials across lung cancer, breast cancer, urothelial cancer, and additional solid tumors.
AstraZeneca Strengthens Leadership in Breast Cancer Innovation
The FDA approval further strengthens AstraZeneca’s growing oncology and breast cancer portfolio, which includes multiple targeted therapies, antibody-drug conjugates, PARP inhibitors, and immunotherapies. The company stated that it remains focused on transforming breast cancer into a more manageable disease through biomarker-driven precision medicine approaches and next-generation therapeutic platforms.
Datroway has already been incorporated into the NCCN Clinical Practice Guidelines in Oncology as a Category 1 preferred first-line treatment option for metastatic TNBC patients who are not candidates for immunotherapy. Experts believe the therapy’s strong survival benefits and improved treatment responses may accelerate adoption across oncology centers globally.
With antibody-drug conjugates continuing to reshape cancer treatment strategies, the approval of Datroway highlights the growing importance of targeted oncology biologics in improving outcomes for patients facing highly aggressive cancers with limited treatment choices.
Source: AstraZeneca press release
